WEBULL
News
IOBT
0.3728
+6.51%
0.0228
Weekly Report: what happened at IOBT last week (0202-0206)?
Weekly Report · 19h ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 4d ago
Weekly Report: what happened at IOBT last week (0126-0130)?
Weekly Report · 02/02 10:15
IO Biotech launches strategic review amid major restructuring
TipRanks · 01/30 22:18
IO BIOTECH INC - EXPECTS ONE-TIME CHARGES OF $2.4 MLN TO $2.6 MLN, DURING Q1 2026 - SEC FILING
Reuters · 01/30 21:55
IO Biotech Engages Raymond James and Reduces Workforce
Reuters · 01/30 21:54
IO Biotech retains Raymond James as advisor, to reduce workforce
TipRanks · 01/30 13:35
IO Biotech Implements Cost-Containment And Cash Conservation Measures, Including Workforce Reduction, To Lessen Operating Expenses While Exploring Strategic Alternatives
Benzinga · 01/30 13:20
IO Biotech Cuts Workforce Amid Strategic Review
Reuters · 01/30 13:05
IO BIOTECH INC - ANNOUNCES SIGNIFICANT WORKFORCE REDUCTION
Reuters · 01/30 13:05
IO Biotech Provides Corporate Update
Barchart · 01/30 07:05
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 01/26 21:05
IO Biotech Price Target Cut to $0.50/Share From $3.00 by Piper Sandler
Dow Jones · 01/26 18:13
IO Biotech Cut to Neutral From Overweight by Piper Sandler
Dow Jones · 01/26 18:13
Piper Sandler Downgrades IO Biotech to Neutral, Lowers Price Target to $0.5
Benzinga · 01/26 18:03
Midday Fly By: Minnesota CEOs call for deescalation, Nvidia invests in CoreWeave
TipRanks · 01/26 17:01
Piper downgrades IO Biotech amid strategic alternatives evaluation
TipRanks · 01/26 13:00
Weekly Report: what happened at IOBT last week (0119-0123)?
Weekly Report · 01/26 10:14
IO Biotech downgraded to Neutral from Overweight at Piper Sandler
TipRanks · 01/23 23:40
Biotech Sector Sees Broad After-Hours Gains Amid Quiet News Flow
NASDAQ · 01/23 04:42
More
Webull provides a variety of real-time IOBT stock news. You can receive the latest news about Io Biotech, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About IOBT
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.